News Article | May 17, 2017
BISHOP’S STORTFORD, England--(BUSINESS WIRE)--Dotmatics, a leading provider of scientific informatics solutions and services to the life sciences industry, today announces that Domainex, a small-molecule therapeutics company that provides integrated drug research services to global pharmaceutical, biotechnology and academic partners, has signed a multi-year agreement. Domainex will leverage Dotmatics’ software to analyse and share valuable scientific data across the full range of its offerings, from protein expression through to pre-clinical candidate delivery. Specifically, Domainex will use several key bioinformatics solutions from the Dotmatics 5.0 suite including Browser, Studies, Vortex, Studies Notebook, Register, Inventory, Cascade, Elemental and Biologics Inventory. This state-of-the-art software will be used to provide seamless interconnectivity of biological and chemical competences, to minimise cycle timelines and providing its clients with a more efficient service. “It is great knowing that our investment in the Dotmatics software platform will directly benefit our clients by creating a visual interface capturing data and enabling project decision making in a just-in-time manner,” said Tom Mander, Domainex COO. “It brings together the innovative and high quality protein expression, hit generation and medicinal chemistry services we offer. This agreement is a natural development of our collaborative working relationships, and we are confident that our two companies will continue to work together in a very positive way for the benefit of our clients.” “Domainex selected Dotmatics because their software is a unique and comprehensive fit with our Biology and Chemistry requirements including the reproduction of assay workflows, data reporting and visualization, and the adoption of electronic lab notebooks,” said Trevor Perrior, Domainex CSO. “We have a history of successfully working with Dotmatics and their ability to integrate seamlessly with our existing systems while providing in-depth, scientifically-advanced software made them the clear choice.” “It is great knowing that our software will help advance Domainex’s innovate work in COPD drug research, epigenetics research, medicinal and computational chemistry services, protein expression and cell based and biochemical assay development offerings,” said Dotmatics’ Chief Executive Officer Steve Gallagher, PhD. “This agreement is a natural progression of our working relationship and we are confident that our two companies will continue on a very positive path.” To learn more about the Dotmatics and Domainex partnership, please visit https://www.dotmatics.com/. Japan-based customers are encouraged to attend the Dotmatics User Group Meeting in Tokyo, May 17th or Osaka on May 19th where Domainex’s Ray Boffey, Group Leader, Medicinal Chemistry, will be speaking about a CRO’s perspective of Dotmatics Implementation. Established in 2001 as a spin-out from University College London, Birkbeck College, and the Institute of Cancer Research, Domainex Ltd. is a Cambridge-based, privately-owned small-molecule therapeutics company that provides integrated drug research services to global pharmaceutical, biotechnology and academic partners. Services cover a wide span of the drug research value chain, from disease target selection to pre-clinical candidate nomination. Domainex's services include recombinant protein expression and use of its proprietary technology platform, Combinatorial Domain Hunting to identify soluble protein fragments for structural biology and assay development. Hit finding activities encompass assay development and screening utilising its BioassayBuilder, FragmentBuilder and LeadBuilder platforms. The core of the service offering is undertaking multi-parameter medicinal chemistry optimisation of hits and leads under the mantra ‘every compound counts’, which can save up to 30% on the average industry time from target to candidate. For more information, please visit www.domainex.co.uk. Dotmatics is a leading global scientific informatics software and services provider, delivering solutions tailored to the modern, highly collaborative and mobile scientific environments. The company provides solutions to several vertical markets, including the pharmaceutical, biotechnology, academia, food and beverage, oil and gas and agrochemical industries. Dotmatics’ enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organisations, from discovery research to development and early manufacturing. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualisation. Dotmatics solutions are available for local or cloud deployment and supported on Microsoft Windows, Mac OS X and Linux. For more information, visit www.dotmatics.com.
News Article | November 10, 2016
ReportsnReports.com adds "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2016" to its store providing comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Complete report on H2 2016 pipeline review of Chronic Obstructive Pulmonary Disease (COPD) with 172 market data tables and 16 figures, spread across 577 pages is available at http://www.reportsnreports.com/reports/743409-chronic-obstructive-pulmonary-disease-copd-pipeline-review-h2-2016.html . Companies discussed in this Chronic Obstructive Pulmonary Disease (COPD) Pipeline Review, H2 2016 report include AB2 Bio Ltd., Abeona Therapeutics, Inc., Ache Laboratorios Farmaceuticos S/A, Achillion Pharmaceuticals, Inc., Adamis Pharmaceuticals Corporation, Advinus Therapeutics Ltd, AlgiPharma AS, Allinky Biopharma, Alteogen Inc., Amakem NV, Ampio Pharmaceuticals, Inc., Angion Biomedica Corp., Apellis Pharmaceuticals Inc, Aridis Pharmaceuticals LLC, Astellas Pharma Inc., AstraZeneca Plc, Asubio Pharma Co., Ltd., Axikin Pharmaceuticals, Inc., Bayer AG, Beech Tree Labs, Inc., Bioneer Corporation, Biotie Therapies Corp., Boehringer Ingelheim GmbH, C4X Discovery Holdings PLC, Carolus Therapeutics, Inc., Cellular Biomedicine Group, Inc., Chiesi Farmaceutici SpA, Circassia Pharmaceuticals Plc, CSL Limited, Cytokinetics, Inc., Daiichi Sankyo Company, Limited, Diffusion Pharmaceuticals Inc., Domainex Limited, Elsalys Biotech SAS, enGene, Inc, Errant Gene Therapeutics, LLC, F. Hoffmann-La Roche Ltd., Foresee Pharmaceuticals, LLC, Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline Plc, Hanmi Pharmaceuticals, Co. Ltd., iCeutica, Inc., InMed Pharmaceuticals Inc., Innate Pharma S.A., INVENT Pharmaceuticals, Inc., Invion Limited, Jiangsu Hansoh Pharmaceutical Co., Ltd., Johnson & Johnson, KaloBios Pharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Ligand Pharmaceuticals, Inc., Medestea Research & Production S.p.A., Merck & Co., Inc., Mereo Biopharma Group Plc, Meridigen Biotech Co., Ltd., Microbion Corporation, Novartis AG, Odan Laboratories Ltd., OPKO Health, Inc., Orion Oyj, Panmira Pharmaceuticals, LLC., Pfizer Inc., PharmaLundensis AB, Pharmaxis Limited, Pila Pharma AB, Polyphor Ltd., Promedior, Inc., ProMetic Life Sciences Inc., Proteostasis Therapeutics, Inc., Pulmagen Therapeutics LLP, Pulmatrix, Inc., Quark Pharmaceuticals, Inc., Re-Pharm Limited, Recipharm AB, Respira Therapeutics Inc, Respiratorius AB, rEVO Biologics, Inc., Rhizen Pharmaceuticals S.A., SATT North SAS, Selvita S.A., Seoul Pharma Co., Ltd., Spring Bank Pharmaceuticals, Inc., Stelic Institute & Co., Inc., sterna biologicals Gmbh & Co KG, Sucampo Pharmaceuticals, Inc., Sun Pharma Advanced Research Company Ltd., Sunovion Pharmaceuticals Inc., Synovo GmbH, Syntrix Biosystems, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., TGV-Laboratories, Therabron Therapeutics, Inc., Theravance Biopharma, Inc., Torrent Pharmaceuticals Limited, U.S. Stem Cell, Inc., Unizyme Laboratories A/S, Vectura Group Plc, Verona Pharma Plc, Vertex Pharmaceuticals Incorporated, Yuhan Corporation, Yungjin Pharm. Co., Ltd. and Zambon Company S.p.A. The Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 1, 13, 40, 29, 81, 25 and 5 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively for Chronic Obstructive Pulmonary Disease (COPD). Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Connect With Us on:
Domainex | Date: 2011-07-18
C Compounds of the general formula (I) and salts thereof are useful in the treatment of diseases associated with aberrant activity of the protein kinases IKK and/or TBK-1: in which: R^(1 )represents an aliphatic heterocyclyl group having 4, 5, 6 or 7 ring atoms, bonded to the phenyl group shown in formula I through a ring nitrogen atom, and optionally substituted by one or more substituents defined in the Specification; R^(2 )represents a phenyl or heteroaryl group which is optionally substituted by one or more substituents defined in the Specification; and each of R^(3 )and R^(4 )independently represents a hydrogen atom or a C_(1-4 )alkyl group.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Smart - Development of Prototype | Award Amount: 250.00K | Year: 2011
Our aim is to invent a new drug for the treatment of several common cancers through inhibition of the enzymes IKKe and/or TBK1. Recent academic research has shown that blocking these closely-related protein kinases will stop cancer cells growing, and force them to die. Furthermore these enzymes are important in some inflamatory diseases, obesity, and Type 2 diabetes. Our initial markets are breast and ovarian cancers. Breast cancer is the most common cancer in women – every year it affects over a million women worldwide - and is the leading cause of death for women aged 40-44. The five-year survival rate for Stage V cancer patients (advanced disease progression) is just 16%. Ovarian cancer is rarely diagnosed in its early stages and is usually quite advanced by the time diagnosis is made, resulting in poor prognoses. The five-year survival rate for all stages is only 35% to 38%. An IKKe/TBK1 inhibitor would have a significant impact on patients with these cancers, leading to better quality of life, and improved five-year survival rates. This drug will also reduce healthcare costs because unlike many existing drugs, this new treatment will be designed to be taken as a pill at home, rather than by infusion in hospital. The objective of this programme is to identify a candidate drug that is effective in disease models and would be orally well-absorbed by humans. The subsequent commercialisation of this new drug would be through a partnership with a large pharmaceutical company with the resources to take on this expensive stage of product development. Domainex is presently a leader in this field. The funding of this proposal will allow Domainex to recruit a number of scientists – preserving highly-skilled drug discovery jobs in the UK. Given recent trends in the pharmaceutical industry it is very likely that the future of drug research in this country will be based largely upon the success and growth of biotechnology companies such as Domainex.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 150.00K | Year: 2012
This project aims to establish the feasibility of a new treatment for Chronic Obstructive Pulmonary Disease – a highly debilitating condition that affects more than 200 million people worldwide and leads to over 6 million early deaths every year. The consequent social, economic, and health-care burden is huge. Treatment for COPD usually involves relieving the symptoms, for example by using drugs delived through an inhaler, or supplementary oxygen, to make breathing easier. However the novel therapeutic mechanism that will be pioneered by this programme will target the processes that cause the disease, which should significantly slow - or even halt - its progression. This key aspect differentiates this approach from that of existing drugs, and of many other experimental treatments.
Domainex | Date: 2014-09-05
Methods for producing and identifying fragments of proteins, and more particularly to methods for generating and identifying soluble protein domains are disclosed based on a method for generating a library of nucleic acid fragments from nucleic acid encoding a desired polypeptide, and more especially a library of essentially, randomly sampled fragments of coding DNA sequence predominantly of defined size range and a method for selecting cloned gene fragments from the library that encode soluble protein domains.
Domainex | Date: 2014-02-21
Compounds of the general formula (I) and salts thereof are useful in the treatment of diseases associated with aberrant activity of the protein kinases IKK and/or TBK-1 in which one of V and W is N, and the other of V and W is CH; and R^(1), R^(2), R^(3 )and R^(4 )are as defined in the specification. The invention also provides uses of the compounds and compositions containing them.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 1.40M | Year: 2014
This project aims to deliver an advanced candidate drug for the treatment for Chronic Obstructive Pulmonary Disease (sometimes refered to as emphysema or chronic bronchitis) – a highly debilitating condition that affects more than 200 million people worldwide and leads to over 6 million early deaths every year. The consequent social, economic, and health-care burden is huge. Treatment for COPD usually involves relieving the symptoms, for example by using drugs delived through an inhaler, or supplementary oxygen, to make breathing easier. However the novel therapeutic mechanism that will be pioneered by this programme can be more conveniently taken as a tablet, rather than inhaled, and will target the processes that cause the disease, which should significantly slow - or even halt - its progression. These key aspects differentiates this approach from that of existing drugs, and of many other experimental treatments.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 150.00K | Year: 2013
Our aim is to establish the feasibility of a new treatment for cancer that works by targeting the enzyme SMYD3. Recent academic research has shown that SMYD3 is not present in normal cells, but in many cancer cells it switches on the production of other proteins that help tumours grow and spread throughout the body. So this work suggests that a drug that inactivates SMYD3 will switch off these mechanisms, and have powerful anti-cancer properties, perhaps with few side-effects. This new mechanism would be very different than those of existing drugs, and of many other experimental treatments. This project will test this idea by identifying SMYD3-blocking compounds, and finding out whether they have the expected effects on tumour cells, and are safe to normal cells. If successful, this project will provide the starting-points for a larger programme to find a drug candidate that works in this way.